Articles from AccuStem Sciences, Inc.

LONDON and PHOENIX, Ariz., April 28, 2025 (GLOBE NEWSWIRE) -- AccuStem Sciences, Inc. (OTCQB: ACUT), a clinical stage diagnostics company dedicated to improving outcomes for patients with or at risk of cancer, and EmeritusDX, a rapidly growing cancer diagnostics and information company, are pleased to announce the expansion of their strategic partnership to include the commercialization of the MSC test for lung cancer screening. This collaboration aims to enhance the accuracy of lung nodule stratification identified via low-dose computed tomography (LDCT), thereby improving patient outcomes and reducing healthcare costs.

LONDON and PHOENIX, Ariz., April 21, 2025 (GLOBE NEWSWIRE) -- AccuStem Sciences, Inc. (OTCQB: ACUT), a clinical stage diagnostics company dedicated to improving outcomes for patients with cancer, announced that its Chairman of the Board, Mr. Gabriele Cerrone, has notified the Company that he has recently purchased an additional 5,000 ACUT shares in the open market. This brings his total holding to 4,915,759 shares.

LONDON and PHOENIX, April 16, 2025 (GLOBE NEWSWIRE) -- AccuStem Sciences, Inc. (OTCQB: ACUT), a clinical stage diagnostics company dedicated to improving outcomes for patients with or at risk of cancer, today announced a development agreement to access blood samples from the multi-institutional, prospective, randomized Rete Italiana di Screening Polmonare (RISP) clinical trial. This study is currently enrolling patients across a clinical network of 18 centers in Italy, and will further demonstrate the impact of AccuStem’s microRNA Signature Classifier (MSC) test in the lung cancer screening setting. The agreement will also provide statistical and analytical support and subject matter expertise to AccuStem to establish and commercialize the MSC test in the US.

LONDON and PHOENIX, April 10, 2025 (GLOBE NEWSWIRE) -- AccuStem Sciences, Inc. (OTCQB: ACUT), a clinical stage diagnostics company dedicated to improving outcomes for patients with cancer, announced that its Chairman of the Board, Mr. Gabriele Cerrone, has notified the Company that he has recently purchased an additional 38,000 ACUT shares in the open market. This brings his total holding to 4,910,759 shares.

LONDON and PHOENIX, April 08, 2025 (GLOBE NEWSWIRE) -- AccuStem Sciences, Inc. (OTCQB: ACUT), a clinical stage diagnostics company dedicated to improving outcomes for patients with cancer, announced that its Chairman of the Board, Mr. Gabriele Cerrone, has notified the Company that he has recently purchased an additional 152,802 ACUT shares in the open market. This brings his total holding to 4,872,759 shares.

LONDON and PHOENIX, April 04, 2025 (GLOBE NEWSWIRE) -- AccuStem Sciences, Inc. (OTCQB: ACUT), a clinical stage diagnostics company dedicated to improving outcomes for patients with or at risk of cancer, announces plans to launch its microRNA Signature Classifier (MSC) blood test for use in the more than 1.6 million US patients diagnosed each year with nodules as part of current lung cancer screening protocols. The company believes it will be able to further expand the use of the test to all of the 15 million at-risk patients who qualify for lung cancer screening annually in the US.

LONDON and PHOENIX, Ariz., March 18, 2025 (GLOBE NEWSWIRE) -- AccuStem Sciences, Inc. (OTCQB: ACUT), a clinical stage diagnostics company dedicated to improving outcomes for patients with or at risk of cancer, announces the acquisition of the license for the proprietary microRNA Signature Classifier (MSC) test. The inventors of the proprietary lung cancer screening test will continue to collaborate and also provide all historic data, research and know-how relating to the Proprietary MSC Test from certain secured creditors and interest holders relating to MSC test.

LONDON and PHOENIX, Ariz., June 06, 2023 (GLOBE NEWSWIRE) -- AccuStem Sciences, Inc. (OTCQB: ACUT), a clinical stage diagnostics company dedicated to improving outcomes for patients with cancer, today announced the establishment of a joint clinical collaboration agreement with University Hospitals.

LONDON and PHOENIX, May 31, 2023 (GLOBE NEWSWIRE) -- AccuStem Sciences, Inc. (OTCQB: ACUT), a clinical stage diagnostics company dedicated to improving outcomes for patients with cancer, today announced a strategic plan to further develop and operationalize the StemPrintER assay.

LONDON and PHOENIX, May 02, 2023 (GLOBE NEWSWIRE) -- AccuStem Sciences, Inc. (OTCQB: ACUT), a clinical stage diagnostics company dedicated to improving outcomes for patients with cancer, announced today that it is taking an extension of time to respond to a formality notice for application 17/907,601 with the US Patent and Trademark Office.

LONDON and PHOENIX, Dec. 06, 2022 (GLOBE NEWSWIRE) -- AccuStem Sciences, Inc. (OTCQB: ACUT), a life sciences company dedicated to improving outcomes for patients with cancer, announced that its Chairman of the Board, Mr. Gabriele Cerrone, has notified the Company that he has recently purchased an additional 3,729 ACUT shares in the open market. This brings his total holding to 3,859,452 shares.

LONDON and PHOENIX, Nov. 22, 2022 (GLOBE NEWSWIRE) -- AccuStem Sciences, Inc. (OTCQB: ACUT), a clinical stage diagnostics company dedicated to improving outcomes for patients with cancer, announced that its Chairman of the Board, Mr. Gabriele Cerrone, has notified the Company that he has recently purchased an additional 24,500 ACUT shares in the open market. This brings his total holding to 3,855,723 shares.

LONDON and PHOENIX, Nov. 16, 2022 (GLOBE NEWSWIRE) -- AccuStem Sciences, Inc. (OTCQB: ACUT), a clinical stage diagnostics company dedicated to improving outcomes for patients with cancer, announced today the appointment of Sean McDonald to its Board of Directors which will now comprise five members.

LONDON and PHOENIX, Oct. 10, 2022 (GLOBE NEWSWIRE) -- AccuStem Sciences, Inc. (OTCQB:ACUT), a clinical stage diagnostics company dedicated to improving outcomes for patients with cancer, announced today that its 2022 annual meeting of stockholders (the “Annual Meeting”) on October 10, 2022 at 9:00 a.m. Eastern Time was convened and adjourned, without any business being conducted, due to lack of the required quorum.